BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 23993303)

  • 1. Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model.
    Geller MA; Knorr DA; Hermanson DA; Pribyl L; Bendzick L; McCullar V; Miller JS; Kaufman DS
    Cytotherapy; 2013 Oct; 15(10):1297-306. PubMed ID: 23993303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mouse Xenograft Model for Intraperitoneal Administration of NK Cell Immunotherapy for Ovarian Cancer.
    Hermanson DL; Bendzick L; Kaufman DS
    Methods Mol Biol; 2016; 1441():277-84. PubMed ID: 27177674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.
    Uppendahl LD; Felices M; Bendzick L; Ryan C; Kodal B; Hinderlie P; Boylan KLM; Skubitz APN; Miller JS; Geller MA
    Gynecol Oncol; 2019 Apr; 153(1):149-157. PubMed ID: 30658847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-ovarian tumor response of donor peripheral blood mononuclear cells is due to infiltrating cytotoxic NK cells.
    Pandey V; Oyer JL; Igarashi RY; Gitto SB; Copik AJ; Altomare DA
    Oncotarget; 2016 Feb; 7(6):7318-28. PubMed ID: 26802025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model.
    Swift BE; Williams BA; Kosaka Y; Wang XH; Medin JA; Viswanathan S; Martinez-Lopez J; Keating A
    Haematologica; 2012 Jul; 97(7):1020-8. PubMed ID: 22271890
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer.
    Felices M; Chu S; Kodal B; Bendzick L; Ryan C; Lenvik AJ; Boylan KLM; Wong HC; Skubitz APN; Miller JS; Geller MA
    Gynecol Oncol; 2017 Jun; 145(3):453-461. PubMed ID: 28236454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells.
    Ferreira-Teixeira M; Paiva-Oliveira D; Parada B; Alves V; Sousa V; Chijioke O; Münz C; Reis F; Rodrigues-Santos P; Gomes C
    BMC Med; 2016 Oct; 14(1):163. PubMed ID: 27769244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15.
    Imamura M; Shook D; Kamiya T; Shimasaki N; Chai SM; Coustan-Smith E; Imai C; Campana D
    Blood; 2014 Aug; 124(7):1081-8. PubMed ID: 25006133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
    Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
    Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer.
    Hermanson DL; Bendzick L; Pribyl L; McCullar V; Vogel RI; Miller JS; Geller MA; Kaufman DS
    Stem Cells; 2016 Jan; 34(1):93-101. PubMed ID: 26503833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity.
    Cichocki F; Valamehr B; Bjordahl R; Zhang B; Rezner B; Rogers P; Gaidarova S; Moreno S; Tuininga K; Dougherty P; McCullar V; Howard P; Sarhan D; Taras E; Schlums H; Abbot S; Shoemaker D; Bryceson YT; Blazar BR; Wolchko S; Cooley S; Miller JS
    Cancer Res; 2017 Oct; 77(20):5664-5675. PubMed ID: 28790065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanded CD56
    Poznanski SM; Nham T; Chew MV; Lee AJ; Hammill JA; Fan IY; Butcher M; Bramson JL; Lee DA; Hirte HW; Ashkar AA
    Cancer Immunol Res; 2018 Oct; 6(10):1174-1185. PubMed ID: 30018043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.
    Liu Y; Wu HW; Sheard MA; Sposto R; Somanchi SS; Cooper LJ; Lee DA; Seeger RC
    Clin Cancer Res; 2013 Apr; 19(8):2132-43. PubMed ID: 23378384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells.
    Nham T; Poznanski SM; Fan IY; Shenouda MM; Chew MV; Lee AJ; Vahedi F; Karimi Y; Butcher M; Lee DA; Hirte H; Ashkar AA
    Cancer Immunol Immunother; 2018 Apr; 67(4):575-587. PubMed ID: 29299659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.
    Geller MA; Cooley S; Judson PL; Ghebre R; Carson LF; Argenta PA; Jonson AL; Panoskaltsis-Mortari A; Curtsinger J; McKenna D; Dusenbery K; Bliss R; Downs LS; Miller JS
    Cytotherapy; 2011 Jan; 13(1):98-107. PubMed ID: 20849361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. hIL-15-gene modified human natural killer cells (NKL-IL15) exhibit anti-human leukemia functions.
    Jiang W; Zhang C; Tian Z; Zhang J
    J Cancer Res Clin Oncol; 2018 Jul; 144(7):1279-1288. PubMed ID: 29737430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rescuing lymphocytes from HLA-G immunosuppressive effects mediated by the tumor microenvironment.
    Wu D; Kuiaste I; Moreau P; Carosella E; Yotnda P
    Oncotarget; 2015 Nov; 6(35):37385-97. PubMed ID: 26460949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
    Jiang W; Zhang C; Tian Z; Zhang J
    Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.